Literature DB >> 19175393

Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy.

Flavia Antonucci1, Yuri Bozzi, Matteo Caleo.   

Abstract

Mesial temporal lobe epilepsy (MTLE) is one of the most common forms of human epilepsy, and it is often resistant to conventional antiepileptic drug (AED) therapy. Here we tested whether a single intrahippocampal administration of the synaptic blocker botulinum neurotoxin E (BoNT/E) is effective in reducing spontaneous recurrent seizures (SRS) in a mouse model of MTLE. Unilateral intrahippocampal injection of kainic acid (KA) in mice was used as a model of MTLE. Electroencephalography (EEG) recordings of SRS were performed during the chronic phase of epilepsy, before and after administration of either BoNT/E or vehicle. Frequency of SRS was significantly decreased for at least 5 days following BoNT/E, but not vehicle, infusion. Our findings demonstrate that BoNT/E can effectively reduce seizure incidence in a mouse model of MTLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175393     DOI: 10.1111/j.1528-1167.2008.01983.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  17 in total

Review 1.  Therapeutic devices for epilepsy.

Authors:  Robert S Fisher
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

2.  Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat.

Authors:  S Bröer; D Zolkowska; M Gernert; M A Rogawski
Journal:  Neuroscience       Date:  2013-07-29       Impact factor: 3.590

3.  Preparation of Cerebellum Granule Neurons from Mouse or Rat Pups and Evaluation of Clostridial Neurotoxin Activity and Their Inhibitors by Western Blot and Immunohistochemistry.

Authors:  Domenico Azarnia Tehran; Marco Pirazzini
Journal:  Bio Protoc       Date:  2018-07-05

4.  ROCK/PKA Inhibition Rescues Hippocampal Hyperexcitability and GABAergic Neuron Alterations in a Oligophrenin-1 Knock-Out Mouse Model of X-Linked Intellectual Disability.

Authors:  Irene Busti; Manuela Allegra; Cristina Spalletti; Chiara Panzi; Laura Restani; Pierre Billuart; Matteo Caleo
Journal:  J Neurosci       Date:  2020-02-25       Impact factor: 6.167

5.  Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.

Authors:  Maciej Gasior; Rebecca Tang; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2013-06-14       Impact factor: 4.030

6.  Intranasal Delivery of Botulinum Neurotoxin A Protects against Hippocampal Neuron Death in the Lithium-Pilocarpine Rat Model.

Authors:  Zhi Huang; Yajun Lian; Yuan Chen; Shuang Li; Haifeng Zhang; Nanchang Xie; Yake Zheng; Shouyi Wu; Yuhan Wang; Wenchao Cheng; Qiaoman Zhang; Chengze Wang; Yinping Shi; Na Xie
Journal:  Neurochem Res       Date:  2019-03-14       Impact factor: 3.996

7.  Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity.

Authors:  Enrico Ferrari; Elizabeth S Maywood; Laura Restani; Matteo Caleo; Marco Pirazzini; Ornella Rossetto; Michael H Hastings; Dhevahi Niranjan; Giampietro Schiavo; Bazbek Davletov
Journal:  Toxins (Basel)       Date:  2011-03-24       Impact factor: 4.546

8.  Epilepsy as a neurodevelopmental disorder.

Authors:  Yuri Bozzi; Simona Casarosa; Matteo Caleo
Journal:  Front Psychiatry       Date:  2012-03-19       Impact factor: 4.157

Review 9.  Emerging opportunities for serotypes of botulinum neurotoxins.

Authors:  Zhongxing Peng Chen; J Glenn Morris; Ramon L Rodriguez; Aparna Wagle Shukla; John Tapia-Núñez; Michael S Okun
Journal:  Toxins (Basel)       Date:  2012-11-07       Impact factor: 4.546

10.  The Chemokine CCL2 Mediates the Seizure-enhancing Effects of Systemic Inflammation.

Authors:  Chiara Cerri; Sacha Genovesi; Manuela Allegra; Francesco Pistillo; Ursula Püntener; Angelo Guglielmotti; V Hugh Perry; Yuri Bozzi; Matteo Caleo
Journal:  J Neurosci       Date:  2016-03-30       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.